期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 7, 期 4, 页码 197-208出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.18
关键词
-
类别
资金
- NHS
- Medical Research Council [G0802325] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0507-10154] Funding Source: researchfish
- MRC [G0802325] Funding Source: UKRI
The molecular and genetic subtyping of cancer has allowed the emergence of individualized therapies. This approach could potentially deliver treatments that have both increased efficacy as well as reduced toxicity. A well-defined subtype of colorectal cancer (CRC) is characterized by a deficiency in the mismatch repair (MMR) pathway. MMR deficiency not only contributes to the pathogenesis of a large proportion of CRC, but also determines the response to many of the drugs that are frequently used to treat this disease. In this Review we describe the MMR deficient phenotype and discuss how a deficiency in this DNA repair process may impact on the management of CRC, including surgery, adjuvant chemotherapy and the choice of systemic agents for the palliation of advanced disease. We also discuss how the DNA repair defect in MMR deficient CRC could be exploited in the development of novel therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据